Related Experiment Video
Updated: Aug 14, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Genetics of alpha 1-antitrypsin deficiency in relation to neonatal liver disease
1MRC Human Biochemical Genetics Unit, Galton Laboratory, University College London, U.K.
Insights
Alpha-1-antitrypsin (AAT) deficiency (PIZZ genotype) is a common genetic disorder in infants, often leading to neonatal hepatitis or cirrhosis. The exact cause of liver damage in PIZZ infants remains unclear, hindering effective treatment and genetic counseling.
Area of Science:
- Genetics
- Hepatology
- Immunology
Background:
- Alpha-1-antitrypsin (AAT) deficiency, specifically the PIZZ genotype, is a prevalent single-gene defect in newborns of European descent.
- Approximately 17% of affected infants present with neonatal hepatitis, and a subset develop severe liver disease, including cirrhosis, potentially leading to liver transplant or childhood mortality.
- The precise pathogenesis of liver disease in AAT deficiency is not fully understood, complicating treatment and genetic counseling strategies.
Purpose of the Study:
- To investigate the genetic and environmental factors contributing to liver disease severity in infants with alpha-1-antitrypsin deficiency (PIZZ genotype).
- To explore potential associations between specific genetic markers, environmental influences, and the clinical course of liver disease in affected newborns.
- To identify reliable methods for predicting disease severity and improving diagnostic approaches for AAT deficiency.
Main Methods:
- Genotyping analysis of the alpha-1-antitrypsin (PI) locus in infants with neonatal disease.
- Correlation studies examining the severity of liver disease in relation to PIZZ genotype and potential familial or environmental factors.
- Investigation of potential associations with HLA class II antigens and the impact of breastfeeding.
Main Results:
- The homozygous PIZZ genotype is the only confirmed genetic association with neonatal liver disease in AAT deficiency.
- The mutation leads to alpha-1-antitrypsin (AAT) protein accumulation within hepatocytes, but additional unidentified factors determine disease severity.
- Evidence suggests potential familial influences on disease severity and a possible protective effect of breastfeeding; HLA class II DR3 antigen positivity is more frequent in affected children.
Conclusions:
- While the PIZZ genotype is necessary for severe liver disease in AAT deficiency, other unidentified factors, possibly immune-related or familial, play a crucial role in disease progression.
- Current methods cannot reliably predict the severity of liver disease in PIZZ infants, impacting parental decisions regarding future pregnancies.
- Accurate diagnosis of the PIZZ genotype via DNA analysis is essential for early identification and management, though therapeutic strategies like AAT replacement require further investigation.
Abstract:
Homozygosity for alpha 1-antitrypsin deficiency, usually of the genotype PIZZ, is one of the more common single gene defects in infants of European origin, occurring in about 1 in 2000 to 1 in 7000 of the newborn population. About 17% of such infants present with neonatal hepatitis and a small number with intracranial haemorrhage thought to be caused by vitamin K deficiency associated with cholestasis. At least 3% of PIZZ infants will die of cirrhosis in later childhood unless successfully treated by liver transplant. The pathogenesis of the liver disease is not understood and this is unsatisfactory both for treatment and for genetic counselling. The locus coding for alpha 1-antitrypsin (alpha 1AT) is designated PI for proteinase inhibitor. Careful study of the genotypes at this locus in neonatal disease shows that the only certain association is with the homozygous PIZZ genotype. The mutation results in a normal rate of synthesis of a polypeptide that becomes entrapped in the endoplasmic reticulum of the hepatocyte. Some other factor (or factors), as yet unidentified, determines whether severe liver damage results. The low level of alpha 1AT in the plasma seems unlikely to be the primary cause of damage but may play a secondary role. There is some evidence that the other factor(s) may be familial since in one study, though not in all, a high correlation for severity of liver disease was found between PIZZ siblings. The heterogeneity of the clinical course does not result from heterogeneity of PIZ alleles and there is no evidence that it is determined by variation in other related genes on chromosome 14. Only two possible clues have emerged so far. There is some evidence of a protective effect of breast-feeding, and a recent study has found the HLA class II DR3 antigen to be more common than expected in children with alpha 1-antitrypsin deficiency and liver disease. Accumulation of alpha 1AT protein in the hepatocytes may predispose them to some unidentified alteration of the immune response. It is possible that lack of antiprotease activity in the plasma might exacerbate the original damage, so the possibility of useful therapy with alpha 1AT cannot be ruled out entirely. At present, there is no valid way of predicting the severity of disease in a PIZZ child; hence, it is common for parents of a severely affected child to wish to terminate any future PIZZ pregnancy. The most direct method to diagnose the PIZZ genotype of a chorion villus sample is by allele-specific hybridization or sequencing of amplified DNA.(ABSTRACT TRUNCATED AT 400 WORDS)
Related Concept Videos
Lethal Alleles
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Inborn Errors of Metabolism
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

